Top Markets
Coin of the day
TherapeuticsMD, Inc. TherapeuticsMD, Inc.

TherapeuticsMD, Inc.

TXMD
Classement en actions #28984
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to... TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Prix de l'action
$2.04
Capitalisation boursière
$23.61M
Changement (1 jour)
1.49%
Changement (1 an)
75.86%
Pays
US
Échange TherapeuticsMD, Inc. (TXMD)

Catégorie

EPS pour TherapeuticsMD, Inc. (TXMD)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de TherapeuticsMD, Inc., l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de TherapeuticsMD, Inc. de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires